{"entity":{"id":"tg-therapeutics","kind":"company","name":"TG Therapeutics","aka":["TG Therapeutics, Inc."],"tldr":"TG Therapeutics is a New York company whose lymphoma drug umbralisib was approved in 2021 and withdrawn in 2022 over a survival signal, and which now sells the anti-CD20 antibody ublituximab for multiple sclerosis.","summary":"TG Therapeutics, listed on Nasdaq, developed the PI3K-delta and CK1-epsilon inhibitor umbralisib (Ukoniq), which received accelerated approval in 2021 for relapsed marginal zone and follicular lymphoma and was withdrawn in 2022 after the UNITY-CLL trial suggested a possible detriment in overall survival, and the glycoengineered anti-CD20 antibody ublituximab, which it had studied with umbralisib in chronic lymphocytic leukaemia and which is now approved as Briumvi for relapsing multiple sclerosis. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.tgtherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by TG Therapeutics","url":"https://clinicaltrials.gov/search?lead=TG%20Therapeutics"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/TG_Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cll","follicular-lymphoma"],"sections":["targeted-therapy"],"technologies":[],"targets":["cd20","pik3cd"],"drugs":["umbralisib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.tgtherapeutics.com","stage":"public","investors":[],"funding":[]},"route":"/companies/tg-therapeutics/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"},{"id":"pik3cd","kind":"target","name":"PI3K delta (PIK3CD)","route":"/targets/pik3cd/"}],"drug":[{"id":"umbralisib","kind":"drug","name":"Umbralisib","route":"/drugs/umbralisib/"}]}}